Technical Analysis for AGE - AgeX Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
C | 2.01 | -4.06% | -0.09 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Down |
Historical AGE trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
50 DMA Support | Bullish | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Fell Below 20 DMA | Bearish | -4.06% | |
Stochastic Reached Oversold | Weakness | -4.06% | |
Wide Bands | Range Expansion | -4.06% | |
Oversold Stochastic | Weakness | -4.06% | |
Bullish Engulfing | Bullish | -10.67% | |
Crossed Above 20 DMA | Bullish | -10.67% | |
Wide Bands | Range Expansion | -10.67% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time | |
---|---|---|
Down 1 ATR | 1 day ago | |
50 DMA Support | 1 day ago | |
3x Volume Pace | 1 day ago | |
2x Volume Pace | 1 day ago | |
1.5x Volume Pace | 1 day ago |
Get a Trading Sidekick!
- Earnings date: ???
AgeX Therapeutics, Inc. Description
AgeX is a biotechnology company focused on the development of novel therapeutics for age-related degenerative disease. AgeX’s mission is to apply the proprietary technology platform related to telomerase-mediated cell immortality and regenerative biology to address a broad range of diseases of aging. The current preclinical development efforts include two cell-based therapies derived from telomerase-positive pluripotent stem cells and two product candidates derived from the company’s proprietary induced Tissue Regeneration (iTR™) technology. AGEX-BAT1 and AGEX-VASC1 are cell-based approaches in the preclinical stage of development comprised of young regenerative cells modified using AgeX’s UniverCyte™ technology facilitating immune tolerance, formulated in HyStem® matrix, designed to correct metabolic imbalances in aging and to restore vascular support in ischemic tissues respectively. AGEX-iTR1547 is a drug-based formulation in preclinical development intended to restore regenerative potential in a wide array of aged tissues afflicted with degenerative disease using the company’s proprietary iTR technology. Renelon™ is a first-generation iTR product designed to promote scarless tissue repair which AgeX plans to initially develop as a topically-administered device for commercial development through a 510(k) application. In addition to the product candidates in early development, AgeX, through its LifeMap subsidiary, currently markets genomic interpretation algorithms. AgeX also markets Cytiva® comprised of PSC-derived heart muscle cells used in screening drugs for efficacy and safety.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Biology Diseases Clinical Development Stem Cells Proprietary Technology Cell Biology Product Design Algorithms Degenerative Disease Tissue Engineering Cloning Telomerase Stem Cell
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 3.93 |
52 Week Low | 0.666 |
Average Volume | 329,477 |
200-Day Moving Average | 1.38 |
50-Day Moving Average | 1.92 |
20-Day Moving Average | 2.23 |
10-Day Moving Average | 2.26 |
Average True Range | 0.20 |
ADX | 39.76 |
+DI | 27.15 |
-DI | 24.00 |
Chandelier Exit (Long, 3 ATRs ) | 2.47 |
Chandelier Exit (Short, 3 ATRs ) | 2.30 |
Upper Bollinger Band | 2.76 |
Lower Bollinger Band | 1.70 |
Percent B (%b) | 0.29 |
BandWidth | 47.22 |
MACD Line | 0.07 |
MACD Signal Line | 0.13 |
MACD Histogram | -0.0567 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.34 | ||||
Resistance 3 (R3) | 2.34 | 2.22 | 2.29 | ||
Resistance 2 (R2) | 2.22 | 2.14 | 2.23 | 2.27 | |
Resistance 1 (R1) | 2.12 | 2.09 | 2.06 | 2.12 | 2.25 |
Pivot Point | 2.00 | 2.00 | 1.98 | 2.01 | 2.00 |
Support 1 (S1) | 1.90 | 1.92 | 1.84 | 1.90 | 1.77 |
Support 2 (S2) | 1.78 | 1.87 | 1.79 | 1.75 | |
Support 3 (S3) | 1.68 | 1.78 | 1.74 | ||
Support 4 (S4) | 1.68 |